What is Plus Therapeutics Inc (PSTV) stock price today?

Plus Therapeutics Inc (PSTV) currently trades at $5.60 per share. The stock has a market capitalization of $40.83M and a P/E ratio of —x.

Is PSTV stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Plus Therapeutics Inc has a Smart Value Score of 19/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Plus Therapeutics Inc's revenue and earnings?

Plus Therapeutics Inc has trailing twelve-month (TTM) revenue of $5.21M with profit margins of 0.00%. Earnings per share (EPS) is $-7.25.

PSTV

Plus Therapeutics Inc

NASDAQ: PSTV · HEALTHCARE · BIOTECHNOLOGY

$5.60

-5.88% today

Updated 2026-04-29

Market cap

$40.83M

P/E ratio

—

P/S ratio

7.83x

EPS (TTM)

$-7.25

Dividend yield

—

52W range

$3 – $24

Volume

3.6M

Market cap

$40.83M

P/E ratio

—

P/S ratio

7.83x

EPS (TTM)

$-7.25

Dividend yield

—

52W range

$3 – $24

Volume

3.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

5.0

Quality

C+

2.5

Profitability

4.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$38.00

+578.57%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-6.29M

- Revenue declining -3.20% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$224000.00	$4.91M	$5.82M	$5.21M	$5.21M
Net income	$-20.27M	$-13.32M	$-12.98M	$-22.39M	$-5.71M
EPS	—	—	—	—	$-7.25
Free cash flow	$-13.73M	$-13.01M	$-10.70M	$-20.84M	$-6.29M
Profit margin	-9,051.34%	-271.04%	-222.84%	-429.43%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
PSTV	$40.83M	19	5.3	2.5	4.7	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Plus Therapeutics Inc trades at $5.60. Our Smart Value Score of 19/100 indicates the stock is weak. TTM revenue stands at $5.21M.

Frequently asked questions

What is Plus Therapeutics Inc's stock price?

Plus Therapeutics Inc (PSTV) trades at $5.60.

Is Plus Therapeutics Inc overvalued?

Smart Value Score 19/100 (Grade F, Strong Sell).

What is the price target of Plus Therapeutics Inc (PSTV)?

The analyst target price is $38.00, representing +578.6% upside from the current price of $5.60.

What is Plus Therapeutics Inc's revenue?

TTM revenue is $5.21M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio7.83x

ROE-522.00%

Beta1.02

50D MA$6.22

200D MA$11.25

Shares out0.01B

Float0.01B

Short ratio—

Avg volume3.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

PSTV vs LLY →PSTV vs JNJ →PSTV vs ABBV →Stock screener →